Eicosanoids and the esophagus

Prostaglandins and Other Lipid Mediators

Volumn 61, Issue 3-4, 2000, Pages 91-104

  Long, John D ^a   Orlando, Roy C ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Sect of Gastroenterol and Hepatol   (United States)

Author keywords

Cyclooxygenase; Digestive tract; Eicosanoid; Esophagus; Leukotriene

Indexed keywords

ACETYLSALICYLIC ACID; FLOSULIDE; ICOSANOID; INDOMETACIN; KETOTIFEN; LEUKOTRIENE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RIOPROSTIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CAT; CONTROLLED STUDY; ESOPHAGITIS; ESOPHAGUS; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; HUMAN; HUMAN TISSUE; NONHUMAN; RABBIT; REFLUX ESOPHAGITIS; REVIEW;

ANIMALS; EICOSANOIDS; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0034120749     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00066-6     Document Type: Review

References (57)

1. Whittle B.J.R., Vane J.R. Prostanoids as regulators of gastrointestinal function. Johnson L.E. Physiology of the gastrointestinal tract. 2nd ed. 1987;143-180 Raven Press, New York.
2. Eberhart C.E., Dubois R.N. Eicosanoids and the gastrointestinal tract. Gastroenterology. 109:1995;285-301.
3. Ottignon Y., Deschamps J.P. Gas chromatographic/mass spectrometric quantitative analysis of eicosanoids in human oesophageal mucosa. Biomed Environ Mass Spectrom. 16:1988;299-304.
4. Boughton-Smith N.K., Hawkey C.J., Whittle B.J.R. Biosynthesis of lipoxygenase and cyclo-oxygenase products from 14C-arachidonic acid by human colonic mucosa. Gut. 24:1983;1176-1182.
5. Moussard C., Alber D., Henry J.C. Profiles of eicosanoid production from 14C-arachidonic acid and prostaglandin metabolism by rabbit esophageal mucosa and muscularis. Prostaglandins Leukotrienes Essent Fatty Acids. 31:1988;31-39.
6. Stein B.E., Schwartzman M.L., Carroll M.A., Rosenthal W.S. Rabbit esophagus metabolizes arachidonic acid predominantly via a lipoxygenase pathway. Prostaglandins Leukotrienes Essent Fatty Acids. 34:1988;75-80.
7. Holtzman M.J., Turk J., Pentland A. A regiospecific monooxygenase with novel stereopreference is the major pathway for arachidonic acid oxygenation in isolated epidermal cells. J Clin Invest. 84:1989;1446-1453.
8. 2 levels in health and in gastroesophageal reflux disease. Prostaglandins Leukotrienes Med. 29:1987;141-151.
9. Sarosiek J., Yu Z., Namiot Z., Rourk R.M., Hetzel D.P., McCallum R.W. Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol. 89:1994;588-594.
10. 2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions. J Clin Gastroenterol. 21:1995;268-274.
11. Triadafilopoulos G., Kaczynska M., Iwane M. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus. Am J Gastroenterol. 91:1996;65-74.
12. 4 in healthy and in esophageal reflux patients. Gastroenterology 1993;104(suppl.):200. Abstract.
13. Suenaga T, Shirakawa T, Katayama N, et al. The role of arachidonate metabolites in rabbit esophagitis. Gastroenterology 1992;102(suppl.):169. Abstract.
14. 4 in rabbit experimental esophagitis. Gastroenterology 1994;106(suppl.):188. Abstract.
15. Kim N., Sohn U.D., Mangannan V., et al. Leukotrienes in acetylcholine-induced contraction of esophageal circular smooth muscle in experimental esophagitis. Gastroenterology. 112:1997;1548-1558.
16. Robert A., Guth P.H., Schmidt K.L., Miller T.A. Cytoprotection. Gastroenterology. 96:1989;548-551.
17. Turjman NA, Powell DW, Orlando RC. Mucosal protective effect of indomethacin against H+ injury in rabbit esophagus. Gastroenterology 1985;88:1020. Abstract.
18. Katz P.O., Geisinger K.R., Hassan M., Wu W.C., Huang D., Castell D.O. Acid-induced esophagitis in cats is prevented by sucralfate but not synthetic prostaglandin E. Dig Dis Sci. 33:1988;217-224.
19. 2 on restitution and proliferation of rabbit esophageal epithelial cells. Dig Dis Sci. 43:1998;2309-2316.
20. Purushotham A.D., Gray G.R., Hansell D.T. Prostaglandins in the treatment of reflux oesophagitis double-blind placebo-controlled clinical trial . J R Coll Surg Edinb. 36:1991;216-218.
21. Duda G., Huesken J.E., Harmon J.W. Effects of prostaglandins on esophageal blood flow. J Surg Res. 44:1988;371-381.
22. Masferrer J.L., Rios A.P., Shwartzman M.L. Inhibition of renal, cardiac, and corneal (Na-K)ATPase by 12(R)-hydroxyeicosatetraenoic acid. Biochem Pharmacol. 39:1990;1971-1974.
23. Long JD, Tobey NA, Orlando RC. Effects of 12-HETE on esophageal epithelial function and resistance to acid injury. J Invest Med 1995;43(suppl. 1):57. Abstract.
24. Stein B.E., Schwartzman M.L., Carroll M.A., Stahl R.E., Rosenthal W.S. Role of arachidonic acid metabolites in acid-pepsin injury to rabbit esophagus. Gastroenterology. 97:1989;278-283.
25. Brown F, Beck B, Fletcher J, Castell D, Eastwood G. Evidence suggesting prostaglandins mediate lower esophageal sphincter (LES) incompetence associated with inflammation. Gastroenterology 1977;72:1033. Abstract.
26. Beck B, Brown F, Fletcher J, Castell D, Eastwood G. Indomethacin promotes healing of experimental esophagitis. Gastroenterology 1978;74:1006. Abstract.
27. Eastwood G.L., Beck B., Castell D.O., Brown F.C., Fletcher J.R. Beneficial effect of indomethacin on acid-induced esophagitis in cats. Dig Dis Sci. 26:1981;601-608.
28. Naya M.J., Pereboom D., Ortego J., Alda J.O., Lanas A. Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits. Gut. 40:1997;175-181.
29. Lanas A.I., Sousa F.L., Ortego J., et al. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol. 7:1995;1065-1072.
30. Lanas A., Hircshowitz B.I. Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol. 13:1991;622-627.
31. Semble E.L. Esophageal injury from nonsteroidal antiinflammatory drugs. Castell D.O. The esophagus. 1992;705-714 Little Brown, Boston.
32. 2, and A2, and of hypovolemic hypotension on the lower esophageal sphincter. Gastroenterology. 65:1973;608-612.
33. 1 on esophageal motility in man. J Appl Physiol. 39:1975;479-481.
34. 2 and to antiinflammatory drugs. Gut. 16:1975;137-143.
35. 1 and prostacyclin in the baboon. Dig Dis Sci. 27:1982;1067-1072.
36. 2 analog, trimoprostil, on esophageal motility in man. Am J Gastroenterol. 82:1987;836-839.
37. 1 analogue, on lower oesophageal sphincter pressure and on the motility of the distal esophagus in healthy volunteers. Scand J Gastroenterol. 24:(suppl. 164):1989;120-126.
38. Tottrup A., Forman A., Raundahl U., Andersson K-E. Effects of prostanoids and indomethacin on isolated smooth muscle from the human lower oesophagus. Pharmacol Toxicol. 71:1992;65-74.
39. 1 effects on resting and cholinergically stimulated lower esophageal sphincter pressure in cats. Prostaglandins. 21:1981;581-590.
40. Eastwood G.L., Castell D.O., Higgs R.H. Experimental esophagitis in cats impairs lower esophageal sphincter pressure. Gastroenterology. 69:1975;146-153.
41. Higgs R.H., Castell D.O., Eastwood G.L. Studies on the mechanism of esophagitis-induced lower esophageal sphincter hypotension in cats. Gastroenterology. 71:1976;51-57.
42. Biancani P., Barwick K., Selling J., McCallum R. Effects of acute experimental esophagitis on mechanical properties of the lower esophageal sphincter. Gastroenterology. 87:1984;8-16.
43. Paterson W.G., Kolyn D.M. Esophageal shortening induced by short-term intraluminal acid perfusion in opossum a cause for hiatus hernia? Gastroenterology. 107:1994;1736-1740.
44. Morgan GP, Williams JG. Prostaglandins as mediators of lower esophageal sphincter dysfunction in esophagitis. Gastroenterology 1993;105:1266-7. Letter.
45. 2 may be a NANC transmitter in the LES. Gastroenterology 1994;106:1397. Letter.
46. Morgan G.P., Williams J.G. Inflammatory mediators in the oesophagus. Gut. 35:1994;297-298.
47. Williams D., Thompson D.G., Heggie L., O'Hanrahan T., Bancewicz J. Esophageal clearance function following treatment of esophagitis. Gastroenterology. 106:1994;108-116.
48. Cagossi M., Salgarello M., Patrignani P., Salgarello G. Effects of various prostaglandin synthesis inhibitors on the tone of the lower oesophageal sphincter in man. Eur J Clin Pharmacol. 43:1992;303-305.
49. Scheiman J.M., Patel P.M., Henson E.K., Nostrant T.T. Effect of naproxen on gastro-esophageal reflux and esophageal function a randomized, double-blind, placebo-controlled study . Am J Gastroenterol. 90:1995;754-757.
50. Sopena F., Lanas A., Sainz R. Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatory drug use. J Clin Gastroenterol. 27:1998;316-320.
51. Cameron A.J. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am. 26:1997;487-494.
52. Marnett L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
53. Wilson K.T., Fu S., Ramanujam K.S., Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58:1998;2929-2934.
54. Zimmermann K.C., Sarbia M., Weber A.-A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:1999;198-204.
55. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res. 53:1992;1322-1327.
56. Funkhouser E.M., Sharp G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer. 76:1995;1116-1119.
57. Farrow D.C., Vaughan T.L., Hansten P.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 7:1998;97-102.